Algeta and Bayer agree $2.9bn sweetened takeover
This article was originally published in Scrip
Norway's Algeta has accepted a takeover bid from partner Bayer after the German group increased its offer by nearly 8%. The bid, which will see Bayer assume full control of the developer of its prostate cancer radiopharmaceutical Xofigo (radium-223 dichloride), has been upped to $2.9bn from $2.4bn.
You may also be interested in...
Advanced Accelerator Applications (AAA) has hit the headlines with recent rumors of a potential acquisition deal from Novartis. Now that the radiopharmaceutical company has its first therapeutic product approved and ready for commercialization, is AAA really ready to sign the dotted line?
In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.